Pharma BD Deal Intelligence

H. Lundbeck A/S / Prexton Therapeutics BV

2018 · Acquisition/Merger · $1.1B · Complete

A total loss: Lundbeck's 2018 acquisition of Prexton Therapeutics for foliglurax, a Phase 2 mGluR4 modulator for Parkinson's OFF-time and dyskinesia, ended in a complete EUR 100M write-off after the drug missed its Phase IIa primary endpoint in 2020—no product ever reached the market.

CALLED IT — OFF BY 24

Total loss: foliglurax failed its Phase II endpoint in 2020 and Lundbeck wrote off the entire ~EUR 100M asset value

Full analysis, sources & comparables →

The coverage arc

Mar 16, 2018 FierceBiotech Neutral

Lundbeck is paying €100M ($123M) up front for Prexton's mid-phase Parkinson's candidate, with up to €805M in milestones. Mid-sized players would have preferred…

Apr 30, 2020 Evaluate Vantage Bearish

Foliglurax's failure in the AMBLED Phase 2 study marks the third major setback in Lundbeck's recent acquisition strategy, with the company writing down the…

Mar 15, 2022 Parkinson's News Today Bearish

Final published Phase 2 AMBLED data confirmed foliglurax failed to reduce OFF-time or dyskinesia versus placebo; Lundbeck discontinued development of the…

Source summaries from our enrichment pipeline; follow links for originals.

All 5 sources with sentiment breakdown →

Lundbeck announced March 2018 acquisition of Swiss biotech Prexton Therapeutics for EUR 100M (~$123M) upfront plus up to EUR 805M (~$992M) in clinical, regulatory and commercial milestones (total up to ~$1.1B). Adds foliglurax, a Phase 2 mGluR4 positive allosteric modulator targeting OFF-time reduction and L-DOPA-induced dyskinesia in Parkinson's disease.

Did it work? Outcome assessment

Total loss: foliglurax failed its Phase II endpoint in 2020 and Lundbeck wrote off the entire ~EUR 100M asset value

Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Lundbeck acquired Prexton in 2018 in a deal worth up to ~€905M (~$1.1B), with the value almost entirely contingent on the lead asset foliglurax. When foliglurax failed its Phase IIa AMBLED trial and was discontinued in March 2020, the acquired program's value was effectively written off, as no other clinical asset of consequence came with Prexton.
Pipeline outcome
Assets Terminated
Foliglurax (PTX002331), an mGluR4 positive allosteric modulator for Parkinson's disease OFF time and dyskinesia, failed the 157-patient Phase IIa AMBLED study: neither the 10mg nor 30mg twice-daily dose separated from placebo on the primary OFF-time endpoint or the dyskinesia secondary endpoint. Lundbeck discontinued the program in March 2020.

Key facts

Disease & market context

Parkinson's Disease (motor complications: OFF-time and L-DOPA-induced dyskinesia)

90K US cases/yr · $1.9B US PD treatment market 2024 · $82.2B Total US economic burden of PD (2024)

Disease Overview

Parkinson's disease is a progressive neurodegenerative disorder caused by loss of dopaminergic neurons in the substantia nigra, producing tremor, bradykinesia, rigidity, and postural instability. Levodopa remains the cornerstone therapy, but chronic use causes motor fluctuations (OFF-time) and dyskinesias that erode quality of life and have driven decades of search for non-dopaminergic adjuncts.

Competitive Landscape

The Parkinson's motor-fluctuation space is crowded but defined by levodopa-delivery innovation, not novel mechanisms. Leading approved options include AbbVie's Duopa (intestinal levodopa-carbidopa gel) and Vyalev (foscarbidopa/foslevodopa, 24-hr SC infusion, FDA-approved Oct 2024); Amneal's Rytary and Crexont (extended-release oral CD/LD, Crexont approved Aug 2024); and adjuncts such as Stalevo (CD/LD/entacapone) and Ongentys (opicapone). Mitsubishi Tanabe's ND0612 (subcutaneous CD/LD) is also in late-stage review. Against this backdrop, Lundbeck's foliglurax was a non-dopaminergic mGluR4 positive allosteric modulator intended to reduce OFF-time without adding to the dopaminergic burden — a potentially first-in-class differentiator that, if successful, would have unlocked a wider patient population earlier in the disease course (Fierce Biotech: https://www.fiercebiotech.com/biotech/lundbeck-to-buy-prexton-for-phase-2-parkinson-s-drug). The deal would have given Lundbeck a non-redundant Parkinson's franchise alongside its broader CNS portfolio. However, the Phase 2a AMBLED study (NCT03162874) failed both primary (OFF-time reduction) and secondary (dyskinesia) endpoints in 2020; Lundbeck wrote down the full EUR 100M asset value and discontinued development, validating skepticism that prior CNS programs had stoked.

Related deals — scored

DealYearValueOutcome
H. Lundbeck A/S / Prexton Therapeutics BV (this deal)2018$1.1B14
H. Lundbeck A/S / Longboard Pharmaceuticals, Inc.2024$2.6B71
H. Lundbeck A/S / Alder BioPharmaceuticals, Inc.2019$1.9B
Novartis AG / Advanced Accelerator Applications S.A.2017$3.9B98
Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program)2015$250M91
Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon)2000$450M89
Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals2015$3.5B86

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →